Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram (ECG) monitoring of alectinib phase I/II pivotal studies.

e20564Background: Alectinib, a potent CNS-active ALK inhibitor, has received accelerated approval by the FDA for patients with ALK+ NSCLC who have progressed on, or are intolerant to, crizotinib. T...